PRINT Technology


  • An inhaled dry powder formulation of treprostinil for pulmonary arterial hypertension (PAH) designed to improve the therapeutic profile of treprostinil by enhancing deep lung delivery and achieving higher dose levels than current inhaled therapies
  • PAH is a rare, chronic, progressive disease caused by hardening and narrowing of the pulmonary arteries that can lead to right heart failure and eventually death, with an estimated prevalence in the United States of approximately 30,000 patients
  • Learn more about the pivotal Phase 3 trial, known as INSPIRE
  • Results of studies with LIQ861 can be found on our ‘Publications’ page


  • Designed to deliver sustained release of bupivacaine, a non opioid anesthetic, to treat local post-operative pain for three to five days through a single administration
  • We have completed two Phase 1 clinical trials and additional toxicology studies to help enable continued clinical development in Phase 2 studies
  • Results of studies with LIQ865 can be found on our ‘Publications’ page


View Publications